 - Participants who have received or plan to receive any additional treatment for glioblastoma aside from surgical resection and conventional radiotherapy including but not limited to temozolomide, stereotactic radiosurgery, placement of Gliadel carmustine; BCNU wafers, any other intratumoral or intracavitary treatment, brachytherapy, bevacizumab, or investigational therapeutic agents 